Mahdieh Mondanizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mahdieh Mondanizadeh has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Behzad Khansarinejad
11 shared publicationsGhasem Mosayebi
Arak Univ Med Sci, Dept Microbiol & Immunol, Arak, Iran
4 shared publicationsMalihe Bagheri
Department of Biotechnology and Molecular Medicine, Faculty of Medicine Arak University of Medical Sciences Arak Iran
4 shared publicationsAlireza Moradabadi
Arak Univ Med Sci, Dept Hematol & Blood Banking, Arak, Iran
3 shared publications- Behzad Khansarinejad
Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
3 shared publications Elham Ghasemi
Department of Biotechnology and Molecular Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- p. 1-27
Diagnostic Significance of microRNA-146 in Asthma: A Systematic Review
- 27 October 2026
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- p. 1-27
Open AccessDiagnostic Significance of microRNA-146 in Asthma: A Systematic Review
- Open Access
- 23 July 2026
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 20 (1)
Harmine-loaded PCL/PVA multilayer nanofibers for targeted pancreatic cancer therapy
- 23 July 2026
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 20 (1)
Open AccessHarmine-loaded PCL/PVA multilayer nanofibers for targeted pancreatic cancer therapy
- 14 March 2026
- Published by Springer Nature in Biotechnology Letters
- Vol. 48 (2)
Antisense oligonucleotides: targeting oncogenic long non-coding RNAs for cancer therapy
This narrative review aims to summarize current evidence on antisense oligonucleotide (ASO)-based strategies targeting oncogenic long non-coding RNAs (lncRNAs) and to evaluate their therapeutic potential in cancer initiation, progression, metastasis, and treatment resistance. A narrative review of preclinical studies was conducted, focusing on ASO-mediated silencing of cancer-associated lncRNAs, including MALAT1, PVT1, NEAT1, and other emerging lncRNAs, across multiple malignancies such as lung, breast, ovarian, gastrointestinal, and head-and-neck cancers. Advances in ASO chemical design and delivery strategies-including lipid and polymeric nanoparticles, ligand-directed conjugates, peptide-based carriers, and gymnotic uptake-were also examined. Preclinical evidence consistently demonstrates that lncRNA-targeted ASOs effectively suppress tumor growth, invasion, metastasis, and chemoresistance while promoting apoptosis. Improvements in ASO chemical modifications and delivery platforms have significantly enhanced ASO stability, biodistribution, and intracellular uptake, thereby improving therapeutic efficacy across diverse cancer models. Targeting oncogenic lncRNAs using ASO-based approaches represents a promising and rapidly evolving strategy in precision oncology. Although substantial progress has been achieved in ASO design and delivery, further optimization and well-structured clinical trials are required to facilitate the translation of these therapies into routine cancer treatment.
- 14 March 2026
- Published by Springer Nature in Biotechnology Letters
- Vol. 48 (2)
Antisense oligonucleotides: targeting oncogenic long non-coding RNAs for cancer therapy
This narrative review aims to summarize current evidence on antisense oligonucleotide (ASO)-based strategies targeting oncogenic long non-coding RNAs (lncRNAs) and to evaluate their therapeutic potential in cancer initiation, progression, metastasis, and treatment resistance. A narrative review of preclinical studies was conducted, focusing on ASO-mediated silencing of cancer-associated lncRNAs, including MALAT1, PVT1, NEAT1, and other emerging lncRNAs, across multiple malignancies such as lung, breast, ovarian, gastrointestinal, and head-and-neck cancers. Advances in ASO chemical design and delivery strategies-including lipid and polymeric nanoparticles, ligand-directed conjugates, peptide-based carriers, and gymnotic uptake-were also examined. Preclinical evidence consistently demonstrates that lncRNA-targeted ASOs effectively suppress tumor growth, invasion, metastasis, and chemoresistance while promoting apoptosis. Improvements in ASO chemical modifications and delivery platforms have significantly enhanced ASO stability, biodistribution, and intracellular uptake, thereby improving therapeutic efficacy across diverse cancer models. Targeting oncogenic lncRNAs using ASO-based approaches represents a promising and rapidly evolving strategy in precision oncology. Although substantial progress has been achieved in ASO design and delivery, further optimization and well-structured clinical trials are required to facilitate the translation of these therapies into routine cancer treatment.
- 11 March 2026
- Published by SAGE Publications in DNA and Cell Biology
Silent Signals: The Expanding Role of Cell-Free DNA in Women’s Health, Pregnancy, and Reproductive Medicine
Cell-free DNA (cfDNA) is an emerging biomarker detectable in various bodily fluids, with promising implications across a wide range of clinical domains. Its minimally invasive nature, short half-life, and ability to reflect tissue-specific genetic and epigenetic alterations position cfDNA as a key tool in women’s health diagnostics. This narrative review aims to explore the biological characteristics, release mechanisms, and clinical utility of cfDNA in gynecological cancers, pregnancy-related disorders, and assisted reproductive technologies (ART), highlighting current applications, benefits, limitations, and future perspectives. A comprehensive literature review was conducted using databases including PubMed, Scopus, Web of Science, and Google Scholar. Relevant peer-reviewed articles from January 2005 to March 2025 were analyzed to summarize advances in cfDNA detection techniques, clinical applications, and emerging technologies in women’s health. In gynecology, cfDNA—especially circulating tumor DNA—has shown promise in early cancer detection, mutation analysis, and disease monitoring. In prenatal medicine, fetal cfDNA (cffDNA) in maternal plasma enables highly accurate, noninvasive screening for chromosomal abnormalities and pregnancy complications such as preeclampsia and intrauterine growth restriction. In reproductive medicine, cfDNA derived from follicular fluid and embryo culture media may serve as a novel biomarker for assessing oocyte and embryo quality. cffDNA offers a noninvasive method for fetal genetic evaluation in pregnancy loss cases, enabling the detection of chromosomal abnormalities to inform clinical management. Technological innovations such as fragmentomics, methylation analysis, and artificial intelligence are enhancing the analytical power and clinical relevance of cfDNA. cfDNA offers a transformative, noninvasive approach for improving diagnosis, prognosis, and personalized care in women’s health. While clinical implementation still faces technical and standardization challenges, emerging tools and multi-omics integration are expected to strengthen the role of cfDNA in precision medicine. Future large-scale studies and validation across diverse populations are essential to support its routine clinical adoption.
- 11 March 2026
- Published by SAGE Publications in DNA and Cell Biology
Silent Signals: The Expanding Role of Cell-Free DNA in Women’s Health, Pregnancy, and Reproductive Medicine
Cell-free DNA (cfDNA) is an emerging biomarker detectable in various bodily fluids, with promising implications across a wide range of clinical domains. Its minimally invasive nature, short half-life, and ability to reflect tissue-specific genetic and epigenetic alterations position cfDNA as a key tool in women’s health diagnostics. This narrative review aims to explore the biological characteristics, release mechanisms, and clinical utility of cfDNA in gynecological cancers, pregnancy-related disorders, and assisted reproductive technologies (ART), highlighting current applications, benefits, limitations, and future perspectives. A comprehensive literature review was conducted using databases including PubMed, Scopus, Web of Science, and Google Scholar. Relevant peer-reviewed articles from January 2005 to March 2025 were analyzed to summarize advances in cfDNA detection techniques, clinical applications, and emerging technologies in women’s health. In gynecology, cfDNA—especially circulating tumor DNA—has shown promise in early cancer detection, mutation analysis, and disease monitoring. In prenatal medicine, fetal cfDNA (cffDNA) in maternal plasma enables highly accurate, noninvasive screening for chromosomal abnormalities and pregnancy complications such as preeclampsia and intrauterine growth restriction. In reproductive medicine, cfDNA derived from follicular fluid and embryo culture media may serve as a novel biomarker for assessing oocyte and embryo quality. cffDNA offers a noninvasive method for fetal genetic evaluation in pregnancy loss cases, enabling the detection of chromosomal abnormalities to inform clinical management. Technological innovations such as fragmentomics, methylation analysis, and artificial intelligence are enhancing the analytical power and clinical relevance of cfDNA. cfDNA offers a transformative, noninvasive approach for improving diagnosis, prognosis, and personalized care in women’s health. While clinical implementation still faces technical and standardization challenges, emerging tools and multi-omics integration are expected to strengthen the role of cfDNA in precision medicine. Future large-scale studies and validation across diverse populations are essential to support its routine clinical adoption.
- Open Access
- 1 October 2025
- Published by National Academy of Sciences of Tajikistan in Preventive Care In Nursing and Midwifery Journal
- Vol. 15 (3) , 14-23
Psychological resilience as a mediator in infertile women: A structural equation modeling analysis of self-efficacy, stigma, and fertility quality of life
Background: Infertility poses significant psychosocial challenges for women, profoundly impacting their well-being and quality of life. Infertility stigma and self-efficacy, reflecting a woman's confidence in managing infertility-related challenges, are key factors influencing this experience. Objectives: This study examined the mediating role of psychological resilience in the associations between infertility stigma, infertility self-efficacy, and fertility-related quality of life (FertiQoL) among infertile women. Methods: A cross-sectional, correlational design was employed, involving 295 infertile women recruited via convenience sampling from fertility clinics in Ahvaz, Iran, in 2024. Data were collected using the Fertility Quality of Life (FertiQoL) scale, Infertility Stigma Scale (ISS), Infertility Self-Efficacy Scale (ISES), and Connor-Davidson Resilience Scale (CD-RISC). Structural Equation Modeling (SEM) was conducted using SPSS and AMOS software to analyze relationships. Results: The model demonstrated a strong fit to the data. Direct paths from infertility stigma and selfefficacy to FertiQoL were non-significant. However, significant direct associations were found between infertility stigma and resilience (β=-0.22, P<0.001), and between self-efficacy and resilience (β=0.24, P<0.001). Psychological resilience significantly mediated the relationships between infertility stigma and FertiQoL (β=-0.06, P=0.001), and between self-efficacy and FertiQoL (β=0.01, P=0.001), indicating its critical role in these pathways. The final structural model exhibited good fit to the data (χ²/df=1.60, CFI=0.94, RMSEA=0.04). Conclusion: Psychological resilience serves as a vital protective factor, mitigating the adverse effects of infertility stigma and enhancing the positive influence of self-efficacy on FertiQoL. These findings underscore the importance of fostering resilience in clinical interventions to improve psychological wellbeing and quality of life among infertile women. Implications for Nursing and Midwifery Preventive Care Psychological resilience plays a pivotal role in enhancing FertiQoL among infertile women. Nursing interventions should prioritize resilience-building strategies, such as cognitivebehavioral therapy and mindfulness, to alleviate infertility stigma. Targeted support to enhance self-efficacy further strengthens resilience and emotional well-being. Resilience-focused holistic care empowers women to effectively navigate infertility challenges.
- 1 October 2025
- Published by National Academy of Sciences of Tajikistan in Preventive Care In Nursing and Midwifery Journal
- Vol. 15 (3) , 14-23
Open AccessPsychological resilience as a mediator in infertile women: A structural equation modeling analysis of self-efficacy, stigma, and fertility quality of life
Background: Infertility poses significant psychosocial challenges for women, profoundly impacting their well-being and quality of life. Infertility stigma and self-efficacy, reflecting a woman's confidence in managing infertility-related challenges, are key factors influencing this experience. Objectives: This study examined the mediating role of psychological resilience in the associations between infertility stigma, infertility self-efficacy, and fertility-related quality of life (FertiQoL) among infertile women. Methods: A cross-sectional, correlational design was employed, involving 295 infertile women recruited via convenience sampling from fertility clinics in Ahvaz, Iran, in 2024. Data were collected using the Fertility Quality of Life (FertiQoL) scale, Infertility Stigma Scale (ISS), Infertility Self-Efficacy Scale (ISES), and Connor-Davidson Resilience Scale (CD-RISC). Structural Equation Modeling (SEM) was conducted using SPSS and AMOS software to analyze relationships. Results: The model demonstrated a strong fit to the data. Direct paths from infertility stigma and selfefficacy to FertiQoL were non-significant. However, significant direct associations were found between infertility stigma and resilience (β=-0.22, P<0.001), and between self-efficacy and resilience (β=0.24, P<0.001). Psychological resilience significantly mediated the relationships between infertility stigma and FertiQoL (β=-0.06, P=0.001), and between self-efficacy and FertiQoL (β=0.01, P=0.001), indicating its critical role in these pathways. The final structural model exhibited good fit to the data (χ²/df=1.60, CFI=0.94, RMSEA=0.04). Conclusion: Psychological resilience serves as a vital protective factor, mitigating the adverse effects of infertility stigma and enhancing the positive influence of self-efficacy on FertiQoL. These findings underscore the importance of fostering resilience in clinical interventions to improve psychological wellbeing and quality of life among infertile women. Implications for Nursing and Midwifery Preventive Care Psychological resilience plays a pivotal role in enhancing FertiQoL among infertile women. Nursing interventions should prioritize resilience-building strategies, such as cognitivebehavioral therapy and mindfulness, to alleviate infertility stigma. Targeted support to enhance self-efficacy further strengthens resilience and emotional well-being. Resilience-focused holistic care empowers women to effectively navigate infertility challenges.
- Open Access
- 28 May 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review
Background: Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options. Despite progress in therapy, there is a requirement for new methods to enhance patient outcomes. Doxorubicin (DOX), a type of anthracycline that has been proven to be effective in different cancers, encounters difficulties in treating glioma because of the blood–brain barrier. This systematic review is intended to assess the effects of DOX on the survival and quality of life of glioma patients. Methods: We conducted a thorough search and found 1576 records, from which 10 studies met our inclusion criteria. These studies, published between 1973 and 2023, were examined for overall survival (OS), progression-free survival (PFS), median time to progression (mTTP), response rate, and toxicity profiles. Results: The studies included in the analysis showed that OS ranged from 6 to 18.5 months, indicating potential improved outcomes with liposomal and PEGylated forms of DOX. PFS rates varied from 15 to 58%, and mTTP ranged from 11 to 39.83 weeks. Response rates varied from 19 to 88%, and while DOX was generally well-tolerated, some hematological and non-hematological toxicities were observed. DOX shows promise in prolonging survival and slowing glioma progression, especially with advanced delivery methods. Conclusions: However, variations in research, small sample sizes, and lack of uniformity highlight the need for further investigation. Overcoming these limitations in future studies is crucial to maximize DOX's effectiveness in glioma treatment and improve patient outcomes.
- 28 May 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
Open AccessExploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review
Background: Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options. Despite progress in therapy, there is a requirement for new methods to enhance patient outcomes. Doxorubicin (DOX), a type of anthracycline that has been proven to be effective in different cancers, encounters difficulties in treating glioma because of the blood–brain barrier. This systematic review is intended to assess the effects of DOX on the survival and quality of life of glioma patients. Methods: We conducted a thorough search and found 1576 records, from which 10 studies met our inclusion criteria. These studies, published between 1973 and 2023, were examined for overall survival (OS), progression-free survival (PFS), median time to progression (mTTP), response rate, and toxicity profiles. Results: The studies included in the analysis showed that OS ranged from 6 to 18.5 months, indicating potential improved outcomes with liposomal and PEGylated forms of DOX. PFS rates varied from 15 to 58%, and mTTP ranged from 11 to 39.83 weeks. Response rates varied from 19 to 88%, and while DOX was generally well-tolerated, some hematological and non-hematological toxicities were observed. DOX shows promise in prolonging survival and slowing glioma progression, especially with advanced delivery methods. Conclusions: However, variations in research, small sample sizes, and lack of uniformity highlight the need for further investigation. Overcoming these limitations in future studies is crucial to maximize DOX's effectiveness in glioma treatment and improve patient outcomes.
- 23 April 2025
- Published by Elsevier in Gene Reports
- Vol. 40
Correlation of miRNA-124-3p and SP1 expression levels in spinal cord injury
- 23 April 2025
- Published by Elsevier in Gene Reports
- Vol. 40
Correlation of miRNA-124-3p and SP1 expression levels in spinal cord injury
- Open Access
- 31 March 2025
- Published by Xia & He Publishing in Gene Expression
- Vol. 000 (000) , 000
MicroRNA-124-3p and Brain-derived Neurotrophic Factor in Rat Spinal Cord Injury: Inverse Expression Pattern
Spinal cord injury (SCI) significantly impacts the central nervous system, with limited effective treatments available. Brain-derived neurotrophic factor (BDNF) plays a crucial role in neuronal growth, survival, and regeneration after SCI. MicroRNAs, particularly miR-124-3p, have been implicated in SCI pathophysiology. However, the relationship between miR-124-3p and BDNF in the context of SCI remains unclear. This study aimed to investigate the correlation between miR-124-3p expression and BDNF levels in a rat model of spinal cord injury and to assess how the timing of injury affects this relationship.
- 31 March 2025
- Published by Xia & He Publishing in Gene Expression
- Vol. 000 (000) , 000
Open AccessMicroRNA-124-3p and Brain-derived Neurotrophic Factor in Rat Spinal Cord Injury: Inverse Expression Pattern
Spinal cord injury (SCI) significantly impacts the central nervous system, with limited effective treatments available. Brain-derived neurotrophic factor (BDNF) plays a crucial role in neuronal growth, survival, and regeneration after SCI. MicroRNAs, particularly miR-124-3p, have been implicated in SCI pathophysiology. However, the relationship between miR-124-3p and BDNF in the context of SCI remains unclear. This study aimed to investigate the correlation between miR-124-3p expression and BDNF levels in a rat model of spinal cord injury and to assess how the timing of injury affects this relationship.
- Open Access
- 1 December 2024
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (12) , 4299-4303
Quantification of the Most Effective X-Ray Dosage for Inhibiting Invasion of Glioma Cell Line
Background: One key feature that distinguishes cancerous cell populations from their normal counterparts is a heightened tendency towards uncontrolled growth and invasive activity. Therapeutic techniques like radiotherapy can impact the viability and invasive behavior of cancer cells by modifying the structure of DNA and inducing programmed cell death. Methods: This research is an experimental study and involved a comprehensive investigation into the effects of 6MV X-ray radiotherapy on various absorbed doses (ranging from 4 to 10 Gy by steps 2Gy) on toxicity, migration, and colony formation in C6 glioblastoma cellular cultures. Results: Our detailed analysis revealed that the cytotoxic responses increased in a dose-dependent manner, while there was a significant decrease in both the ability to migrate and form colonies in the C6 cell line. Conclusions: This thorough examination provides new insights into the way malignant cell populations respond to ionizing radiation in a dose-dependent manner within a clinical setting. By directly impacting cellular functions and causing disturbances, this occurrence leads to a slowing down of disease progression.
- 1 December 2024
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (12) , 4299-4303
Open AccessQuantification of the Most Effective X-Ray Dosage for Inhibiting Invasion of Glioma Cell Line
Background: One key feature that distinguishes cancerous cell populations from their normal counterparts is a heightened tendency towards uncontrolled growth and invasive activity. Therapeutic techniques like radiotherapy can impact the viability and invasive behavior of cancer cells by modifying the structure of DNA and inducing programmed cell death. Methods: This research is an experimental study and involved a comprehensive investigation into the effects of 6MV X-ray radiotherapy on various absorbed doses (ranging from 4 to 10 Gy by steps 2Gy) on toxicity, migration, and colony formation in C6 glioblastoma cellular cultures. Results: Our detailed analysis revealed that the cytotoxic responses increased in a dose-dependent manner, while there was a significant decrease in both the ability to migrate and form colonies in the C6 cell line. Conclusions: This thorough examination provides new insights into the way malignant cell populations respond to ionizing radiation in a dose-dependent manner within a clinical setting. By directly impacting cellular functions and causing disturbances, this occurrence leads to a slowing down of disease progression.